drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB14962 | DB15091 | 1,363 | 676 | [
"DDInter1847",
"DDInter1901"
] | Trastuzumab deruxtecan | Upadacitinib | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1363,
25,
676
]
],
[
[
1363,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1363,
63,
1184
],
[
1184,
25,
676
]
],
[
[
1363,
64,
1064
],
[
1064,... | [
[
[
"Trastuzumab deruxtecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Trastuzumab deruxtecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
... | Trastuzumab deruxtecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Trastuzumab deruxtecan may cause a moderate interaction that could exacerbate diseases when ta... |
DB00852 | DB13139 | 1,445 | 1,032 | [
"DDInter1545",
"DDInter1063"
] | Pseudoephedrine | Levosalbutamol | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1445,
24,
1032
]
],
[
[
1445,
63,
73
],
[
73,
24,
1032
]
],
[
[
1445,
1,
22
],
[
22,
24,
1032
]
],
[
[
1445,
74,
1466
],
[
1466,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interact... |
DB00446 | DB06215 | 597 | 1,353 | [
"DDInter351",
"DDInter730"
] | Chloramphenicol | Ferumoxytol | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) . It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isoto... | Moderate | 1 | [
[
[
597,
24,
1353
]
],
[
[
597,
24,
1596
],
[
1596,
24,
1353
]
],
[
[
597,
24,
428
],
[
428,
63,
1353
]
],
[
[
597,
24,
1596
],
[
1596,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferumoxytol"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Ferumoxytol
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and F... |
DB01259 | DB09049 | 392 | 1,135 | [
"DDInter1024",
"DDInter1261"
] | Lapatinib | Naloxegol | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
392,
23,
1135
]
],
[
[
392,
24,
807
],
[
807,
23,
1135
]
],
[
[
392,
64,
33
],
[
33,
23,
1135
]
],
[
[
392,
24,
1406
],
[
1406,
... | [
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
],
[
"... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal and Ulipristal may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Lapatinib may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a min... |
DB00085 | DB11256 | 639 | 95 | [
"DDInter1384",
"DDInter1058"
] | Pancrelipase | Levomefolic acid (calcium) | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further informa... | 5-methyltetrahydrofolic acid is a tetrahydrofolic acid that is 5,6,7,8-tetrahydrofolic acid substituted by a methyl group at position 5. It has a role as a human metabolite. It is functionally related to a 5,6,7,8-tetrahydrofolic acid. It is a conjugate acid of a 5-methyltetrahydrofolate(2-). | Moderate | 1 | [
[
[
639,
24,
95
]
],
[
[
639,
24,
356
],
[
356,
23,
50
],
[
50,
23,
95
]
],
[
[
639,
24,
356
],
[
356,
35,
663
],
[
663,
24,
95
... | [
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomefolic acid"
]
],
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
]... | Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Levomefolic acid
Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid may cause a minor interaction that can limit clinical effects when taken with Sulfasalazine... |
DB01035 | DB09472 | 1,401 | 1,383 | [
"DDInter1524",
"DDInter1693"
] | Procainamide | Sodium sulfate | A derivative of procaine with less CNS action. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Major | 2 | [
[
[
1401,
25,
1383
]
],
[
[
1401,
25,
609
],
[
609,
24,
1383
]
],
[
[
1401,
24,
1311
],
[
1311,
24,
1383
]
],
[
[
1401,
64,
521
],
[
521,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromyci... | Procainamide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and M... |
DB00295 | DB00669 | 475 | 399 | [
"DDInter1244",
"DDInter1730"
] | Morphine | Sumatriptan | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992. | Moderate | 1 | [
[
[
475,
24,
399
]
],
[
[
475,
24,
1541
],
[
1541,
40,
399
]
],
[
[
475,
24,
767
],
[
767,
1,
399
]
],
[
[
475,
6,
4973
],
[
4973,
4... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sumatriptan"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naratriptan"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naratriptan and Naratriptan (Compound) resembles Sumatriptan (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Zolmitriptan and Zolmitriptan (Compound) resembles Sumatriptan (Compou... |
DB01319 | DB08912 | 34 | 1,040 | [
"DDInter777",
"DDInter462"
] | Fosamprenavir | Dabrafenib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
34,
24,
1040
]
],
[
[
34,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
34,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
34,
63,
168
],
[
168,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Fosamprenavir (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00619 | DB11560 | 1,419 | 1,678 | [
"DDInter909",
"DDInter1038"
] | Imatinib | Lesinurad | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Moderate | 1 | [
[
[
1419,
24,
1678
]
],
[
[
1419,
24,
466
],
[
466,
63,
1678
]
],
[
[
1419,
63,
522
],
[
522,
24,
1678
]
],
[
[
1419,
24,
263
],
[
263,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirl... |
DB00500 | DB09054 | 24 | 384 | [
"DDInter1831",
"DDInter905"
] | Tolmetin | Idelalisib | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
24,
24,
384
]
],
[
[
24,
24,
222
],
[
222,
23,
384
]
],
[
[
24,
25,
1618
],
[
1618,
24,
384
]
],
[
[
24,
63,
305
],
[
305,
24,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Tolmetin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause ... |
DB00470 | DB00683 | 530 | 1,382 | [
"DDInter601",
"DDInter1212"
] | Dronabinol | Midazolam | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
530,
24,
1382
]
],
[
[
530,
24,
1216
],
[
1216,
40,
1382
]
],
[
[
530,
63,
902
],
[
902,
40,
1382
]
],
[
[
530,
6,
8374
],
[
8374,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Dronab... |
DB01030 | DB08875 | 869 | 1,618 | [
"DDInter1835",
"DDInter262"
] | Topotecan | Cabozantinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
869,
24,
1618
]
],
[
[
869,
24,
384
],
[
384,
63,
1618
]
],
[
[
869,
63,
1668
],
[
1668,
24,
1618
]
],
[
[
869,
24,
165
],
[
165,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lena... |
DB00004 | DB05679 | 669 | 1,683 | [
"DDInter499",
"DDInter1907"
] | Denileukin diftitox | Ustekinumab | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
669,
24,
1683
]
],
[
[
669,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
669,
24,
4
],
[
4,
24,
1683
]
],
[
[
669,
25,
770
],
[
770,
24... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Omacet... |
DB00486 | DB01192 | 1,614 | 560 | [
"DDInter1253",
"DDInter1372"
] | Nabilone | Oxymorphone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
1614,
24,
560
]
],
[
[
1614,
24,
828
],
[
828,
1,
560
]
],
[
[
1614,
63,
421
],
[
421,
1,
560
]
],
[
[
1614,
21,
28695
],
[
28695,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxymorphone (Compound... |
DB00313 | DB08880 | 556 | 1,510 | [
"DDInter1913",
"DDInter1771"
] | Valproic acid | Teriflunomide | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
556,
25,
1510
]
],
[
[
556,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
556,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
556,
23,
752
],
[
752,
... | [
[
[
"Valproic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Al... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide an... |
DB00005 | DB13007 | 1,057 | 1,060 | [
"DDInter687",
"DDInter642"
] | Etanercept | Enfortumab vedotin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
1057,
25,
1060
]
],
[
[
1057,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1057,
25,
270
],
[
270,
24,
1060
]
],
[
[
1057,
25,
1011
],
[
1011... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Cr... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Etanercept may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab ... |
DB01149 | DB11978 | 851 | 124 | [
"DDInter1274",
"DDInter822"
] | Nefazodone | Glasdegib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
851,
25,
124
]
],
[
[
851,
25,
1135
],
[
1135,
23,
124
]
],
[
[
851,
23,
466
],
[
466,
62,
124
]
],
[
[
851,
63,
475
],
[
475,
2... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ... | Nefazodone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a m... |
DB00562 | DB09134 | 1,014 | 1,552 | [
"DDInter188",
"DDInter966"
] | Benzthiazide | Ioversol | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Moderate | 1 | [
[
[
1014,
24,
1552
]
],
[
[
1014,
40,
674
],
[
674,
24,
1552
]
],
[
[
1014,
1,
811
],
[
811,
24,
1552
]
],
[
[
1014,
63,
1648
],
[
1648,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} m... | Benzthiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Benzthiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when take... |
DB08881 | DB11689 | 868 | 321 | [
"DDInter1925",
"DDInter1659"
] | Vemurafenib | Selumetinib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
868,
24,
321
]
],
[
[
868,
25,
982
],
[
982,
63,
321
]
],
[
[
868,
64,
392
],
[
392,
24,
321
]
],
[
[
868,
25,
498
],
[
498,
24,... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivoside... | Vemurafenib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Vemurafenib may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate int... |
DB00731 | DB01367 | 1,144 | 1,163 | [
"DDInter1269",
"DDInter1572"
] | Nateglinide | Rasagiline | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
1144,
24,
1163
]
],
[
[
1144,
21,
28714
],
[
28714,
60,
1163
]
],
[
[
1144,
63,
590
],
[
590,
24,
1163
]
],
[
[
1144,
24,
401
],
[
401... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Nateglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caus... | Nateglinide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Rasagiline (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with R... |
DB01284 | DB06674 | 1,042 | 908 | [
"DDInter1782",
"DDInter837"
] | Tetracosactide | Golimumab | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1042,
25,
908
]
],
[
[
1042,
63,
336
],
[
336,
24,
908
]
],
[
[
1042,
24,
1586
],
[
1586,
63,
908
]
],
[
[
1042,
24,
1136
],
[
1136,
... | [
[
[
"Tetracosactide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nif... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine ... |
DB00501 | DB12130 | 752 | 1,017 | [
"DDInter380",
"DDInter1094"
] | Cimetidine | Lorlatinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
752,
24,
1017
]
],
[
[
752,
63,
608
],
[
608,
23,
1017
]
],
[
[
752,
23,
271
],
[
271,
23,
1017
]
],
[
[
752,
63,
590
],
[
590,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron m... |
DB00802 | DB06209 | 1,322 | 256 | [
"DDInter43",
"DDInter1508"
] | Alfentanil | Prasugrel | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
1322,
24,
256
]
],
[
[
1322,
6,
8374
],
[
8374,
45,
256
]
],
[
[
1322,
21,
28681
],
[
28681,
60,
256
]
],
[
[
1322,
63,
752
],
[
752,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfentanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Alfentanil (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Cimetid... |
DB01234 | DB12001 | 1,220 | 564 | [
"DDInter513",
"DDInter7"
] | Dexamethasone | Abemaciclib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1220,
24,
564
]
],
[
[
1220,
63,
536
],
[
536,
24,
564
]
],
[
[
1220,
24,
868
],
[
868,
24,
564
]
],
[
[
1220,
25,
1017
],
[
1017,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafeni... |
DB00445 | DB00938 | 322 | 455 | [
"DDInter655",
"DDInter1635"
] | Epirubicin | Salmeterol | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
322,
24,
455
]
],
[
[
322,
24,
1523
],
[
1523,
25,
455
]
],
[
[
322,
24,
688
],
[
688,
63,
455
]
],
[
[
322,
7,
8606
],
[
8606,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a ... |
DB00404 | DB09154 | 523 | 1,475 | [
"DDInter54",
"DDInter1686"
] | Alprazolam | Sodium citrate | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
523,
23,
1475
]
],
[
[
523,
1,
902
],
[
902,
23,
1475
]
],
[
[
523,
40,
1382
],
[
1382,
23,
1475
]
],
[
[
523,
24,
478
],
[
478,
... | [
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
],
[
"Clobazam",
"{u} may cause a minor int... | Alprazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Al... |
DB00867 | DB06603 | 1,052 | 39 | [
"DDInter1606",
"DDInter1387"
] | Ritodrine | Panobinostat | Adrenergic beta-agonist used to control premature labor. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1052,
25,
39
]
],
[
[
1052,
24,
455
],
[
455,
24,
39
]
],
[
[
1052,
35,
480
],
[
480,
24,
39
]
],
[
[
1052,
24,
144
],
[
144,
63... | [
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ritodrine (Compound) resembles Formoterol (Compound) and Ritodrine may cause a moderate interaction that could ... |
DB00594 | DB00959 | 863 | 1,486 | [
"DDInter68",
"DDInter1191"
] | Amiloride | Methylprednisolone | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
863,
24,
1486
]
],
[
[
863,
24,
175
],
[
175,
40,
1486
]
],
[
[
863,
24,
167
],
[
167,
1,
1486
]
],
[
[
863,
63,
251
],
[
251,
1... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Me... |
DB00903 | DB13928 | 1,680 | 1,385 | [
"DDInter686",
"DDInter1660"
] | Etacrynic acid | Semaglutide | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1680,
24,
1385
]
],
[
[
1680,
63,
891
],
[
891,
24,
1385
]
],
[
[
1680,
24,
1486
],
[
1486,
24,
1385
]
],
[
[
1680,
63,
891
],
[
891,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylpr... |
DB00860 | DB14975 | 891 | 988 | [
"DDInter1513",
"DDInter1949"
] | Prednisolone | Voxelotor | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
891,
24,
988
]
],
[
[
891,
40,
251
],
[
251,
24,
988
]
],
[
[
891,
1,
1486
],
[
1486,
24,
988
]
],
[
[
891,
63,
126
],
[
126,
24... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause ... | Prednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Prednisolone (Compound) resembles Methylprednisolone (Compound) and Methyl
Prednisolone may cause a moderate interaction that could exacerbate diseases w... |
DB00502 | DB04843 | 1,300 | 1,511 | [
"DDInter853",
"DDInter1149"
] | Haloperidol | Mepenzolate | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1300,
24,
1511
]
],
[
[
1300,
24,
537
],
[
537,
24,
1511
]
],
[
[
1300,
63,
352
],
[
352,
24,
1511
]
],
[
[
1300,
24,
649
],
[
649,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospiu... |
DB00420 | DB00912 | 508 | 473 | [
"DDInter1532",
"DDInter1581"
] | Promazine | Repaglinide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
508,
24,
473
]
],
[
[
508,
6,
8374
],
[
8374,
45,
473
]
],
[
[
508,
63,
73
],
[
73,
24,
473
]
],
[
[
508,
40,
216
],
[
216,
24,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Promazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Promazine (Compo... |
DB00398 | DB05316 | 79 | 749 | [
"DDInter1702",
"DDInter1467"
] | Sorafenib | Pimavanserin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
79,
24,
749
]
],
[
[
79,
23,
112
],
[
112,
23,
749
]
],
[
[
79,
24,
1264
],
[
1264,
24,
749
]
],
[
[
79,
63,
521
],
[
521,
24,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin... |
DB01017 | DB11348 | 1,669 | 1,065 | [
"DDInter1224",
"DDInter279"
] | Minocycline | Calcium Phosphate | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1669,
24,
1065
]
],
[
[
1669,
62,
1014
],
[
1014,
24,
1065
]
],
[
[
1669,
40,
1620
],
[
1620,
24,
1065
]
],
[
[
1669,
23,
178
],
[
178... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],... | Minocycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Minocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interac... |
DB00813 | DB01234 | 704 | 1,220 | [
"DDInter722",
"DDInter513"
] | Fentanyl | Dexamethasone | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
704,
25,
1220
]
],
[
[
704,
6,
21998
],
[
21998,
45,
1220
]
],
[
[
704,
10,
11562
],
[
11562,
49,
1220
]
],
[
[
704,
21,
28835
],
[
28... | [
[
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Fentanyl",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compound)... | Fentanyl (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound)
Fentanyl (Compound) palliates prostate cancer (Disease) and prostate cancer (Disease) is palliated by Dexamethasone (Compound)
Fentanyl (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side... |
DB00365 | DB11730 | 839 | 351 | [
"DDInter842",
"DDInter1588"
] | Grepafloxacin | Ribociclib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
839,
25,
351
]
],
[
[
839,
23,
112
],
[
112,
23,
351
]
],
[
[
839,
24,
310
],
[
310,
24,
351
]
],
[
[
839,
23,
372
],
[
372,
24,... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel a... |
DB01320 | DB08880 | 651 | 1,510 | [
"DDInter783",
"DDInter1771"
] | Fosphenytoin | Teriflunomide | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
651,
25,
1510
]
],
[
[
651,
62,
608
],
[
608,
23,
1510
]
],
[
[
651,
24,
129
],
[
129,
63,
1510
]
],
[
[
651,
25,
1033
],
[
1033,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Fosphenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidoca... | Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enz... |
DB00196 | DB01115 | 600 | 336 | [
"DDInter743",
"DDInter1291"
] | Fluconazole | Nifedipine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
600,
24,
336
]
],
[
[
600,
24,
1428
],
[
1428,
1,
336
]
],
[
[
600,
24,
1081
],
[
1081,
40,
336
]
],
[
[
600,
6,
4973
],
[
4973,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compou... |
DB00427 | DB01041 | 1,233 | 770 | [
"DDInter1879",
"DDInter1789"
] | Triprolidine | Thalidomide | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1233,
24,
770
]
],
[
[
1233,
7,
2900
],
[
2900,
46,
770
]
],
[
[
1233,
24,
849
],
[
849,
63,
770
]
],
[
[
1233,
24,
1533
],
[
1533,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Triprolidine",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is upregulated by... | Triprolidine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Thalidomide (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
... |
DB00106 | DB01159 | 618 | 419 | [
"DDInter4",
"DDInter854"
] | Abarelix | Halothane | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
618,
24,
419
]
],
[
[
618,
23,
112
],
[
112,
23,
419
]
],
[
[
618,
24,
1148
],
[
1148,
24,
419
]
],
[
[
618,
24,
477
],
[
477,
6... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halothane
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isopren... |
DB00927 | DB01032 | 1,559 | 824 | [
"DDInter712",
"DDInter1522"
] | Famotidine | Probenecid | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Minor | 0 | [
[
[
1559,
23,
824
]
],
[
[
1559,
24,
1401
],
[
1401,
40,
824
]
],
[
[
1559,
24,
1411
],
[
1411,
63,
824
]
],
[
[
1559,
6,
16560
],
[
16560... | [
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Probenecid"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide (Compound) resembles Probenecid (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that... |
DB00814 | DB08901 | 1,171 | 1,468 | [
"DDInter1143",
"DDInter1492"
] | Meloxicam | Ponatinib | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1171,
25,
1468
]
],
[
[
1171,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
1171,
21,
29024
],
[
29024,
60,
1468
]
],
[
[
1171,
63,
267
],
[
26... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Meloxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"... | Meloxicam (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Meloxicam (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound)
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Nal... |
DB00046 | DB00978 | 1,179 | 739 | [
"DDInter940",
"DDInter1084"
] | Insulin lispro | Lomefloxacin | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Major | 2 | [
[
[
1179,
25,
739
]
],
[
[
1179,
25,
945
],
[
945,
40,
739
]
],
[
[
1179,
25,
1176
],
[
1176,
1,
739
]
],
[
[
1179,
24,
1344
],
[
1344,
... | [
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin"... | Insulin lispro may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Insulin lispro may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Insulin li... |
DB08896 | DB13179 | 292 | 68 | [
"DDInter1576",
"DDInter1882"
] | Regorafenib | Troleandomycin | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
292,
24,
68
]
],
[
[
292,
63,
222
],
[
222,
23,
68
]
],
[
[
292,
63,
267
],
[
267,
24,
68
]
],
[
[
292,
25,
710
],
[
710,
24,
... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and ... |
DB00207 | DB08899 | 1,570 | 129 | [
"DDInter157",
"DDInter649"
] | Azithromycin | Enzalutamide | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1570,
24,
129
]
],
[
[
1570,
24,
918
],
[
918,
1,
129
]
],
[
[
1570,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1570,
21,
28703
],
[
28703,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Azithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Azithromycin (Compound) causes Pruritus (Side Effect) ... |
DB01041 | DB01206 | 770 | 37 | [
"DDInter1789",
"DDInter1086"
] | Thalidomide | Lomustine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Major | 2 | [
[
[
770,
25,
37
]
],
[
[
770,
5,
11555
],
[
11555,
44,
37
]
],
[
[
770,
21,
28675
],
[
28675,
60,
37
]
],
[
[
770,
63,
1176
],
[
1176,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Thalidomide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated ... | Thalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Thalidomide (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Lomustine (Compound)
Thalidomide may cause a moderate interaction that could exace... |
DB00372 | DB01018 | 999 | 1,364 | [
"DDInter1793",
"DDInter847"
] | Thiethylperazine | Guanfacine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
999,
24,
1364
]
],
[
[
999,
24,
390
],
[
390,
1,
1364
]
],
[
[
999,
24,
549
],
[
549,
63,
1364
]
],
[
[
999,
63,
1214
],
[
1214,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanabenz"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Guanabenz and Guanabenz (Compound) resembles Guanfacine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate intera... |
DB00489 | DB01364 | 17 | 22 | [
"DDInter1704",
"DDInter650"
] | Sotalol | Ephedrine | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
17,
24,
22
]
],
[
[
17,
24,
1445
],
[
1445,
1,
22
]
],
[
[
17,
6,
3576
],
[
3576,
45,
22
]
],
[
[
17,
21,
28680
],
[
28680,
60,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Sotalol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Ephedrine (Compound)
Sotalol (Compound) causes Rash (Side Effect) and Rash (Side Effect... |
DB00444 | DB13007 | 63 | 1,060 | [
"DDInter1765",
"DDInter642"
] | Teniposide | Enfortumab vedotin | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
63,
24,
1060
]
],
[
[
63,
24,
129
],
[
129,
23,
1060
]
],
[
[
63,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
63,
63,
58
],
[
58,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib ... |
DB00224 | DB01105 | 215 | 222 | [
"DDInter917",
"DDInter1665"
] | Indinavir | Sibutramine | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Minor | 0 | [
[
[
215,
23,
222
]
],
[
[
215,
6,
8374
],
[
8374,
45,
222
]
],
[
[
215,
18,
4930
],
[
4930,
57,
222
]
],
[
[
215,
21,
28698
],
[
28698,
... | [
[
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Indinavir (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Sibutramine (Compound)
Indinavir (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound)
Indinavi... |
DB00252 | DB00358 | 362 | 1,010 | [
"DDInter1460",
"DDInter1140"
] | Phenytoin | Mefloquine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Moderate | 1 | [
[
[
362,
24,
1010
]
],
[
[
362,
6,
8374
],
[
8374,
45,
1010
]
],
[
[
362,
21,
29362
],
[
29362,
60,
1010
]
],
[
[
362,
24,
1311
],
[
1311,... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Phenytoin (Compound) causes Leukocytosis (Side Effect) and Leukocytosis (Side Effect) is caused by Mefloquine (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide a... |
DB01006 | DB11932 | 300 | 327 | [
"DDInter1040",
"DDInter3"
] | Letrozole | Abametapir (topical) | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
300,
24,
327
]
],
[
[
300,
24,
283
],
[
283,
63,
327
]
],
[
[
300,
63,
1101
],
[
1101,
24,
327
]
],
[
[
300,
24,
1478
],
[
1478,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Letrozole ma... |
DB00286 | DB08889 | 380 | 350 | [
"DDInter439",
"DDInter299"
] | Conjugated estrogens | Carfilzomib | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Major | 2 | [
[
[
380,
25,
350
]
],
[
[
380,
6,
4973
],
[
4973,
45,
350
]
],
[
[
380,
21,
28762
],
[
28762,
60,
350
]
],
[
[
380,
25,
770
],
[
770,
... | [
[
[
"Conjugated estrogens",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Conjugated estrogens (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Conjugated estrogens (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Conjugated estrogens may lead to a major life threatening interaction when taken with Thalid... |
DB04908 | DB09079 | 1,671 | 1,496 | [
"DDInter741",
"DDInter1296"
] | Flibanserin | Nintedanib | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
1671,
24,
1496
]
],
[
[
1671,
24,
741
],
[
741,
63,
1496
]
],
[
[
1671,
64,
609
],
[
609,
24,
1496
]
],
[
[
1671,
25,
913
],
[
913,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Flibanserin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin ... |
DB00295 | DB00489 | 475 | 17 | [
"DDInter1244",
"DDInter1704"
] | Morphine | Sotalol | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Moderate | 1 | [
[
[
475,
24,
17
]
],
[
[
475,
63,
88
],
[
88,
40,
17
]
],
[
[
475,
21,
29647
],
[
29647,
60,
17
]
],
[
[
475,
24,
1054
],
[
1054,
62... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Me... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Morphine (Compound) causes Ache (Side Effect) and Ache (Side Effect) is caused by Sotalol (Compound)
Morphine may cause a moderate interaction that could exacerbate ... |
DB00780 | DB00804 | 551 | 1,507 | [
"DDInter1440",
"DDInter543"
] | Phenelzine | Dicyclomine | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Minor | 0 | [
[
[
551,
23,
1507
]
],
[
[
551,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
551,
64,
1594
],
[
1594,
24,
1507
]
],
[
[
551,
24,
832
],
[
832,
... | [
[
[
"Phenelzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dicyclomine"
]
],
[
[
"Phenelzine",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect... | Phenelzine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Phenelzine may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine... |
DB00222 | DB11228 | 245 | 721 | [
"DDInter825",
"DDInter1184"
] | Glimepiride | Methylcellulose | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum... | Minor | 0 | [
[
[
245,
23,
721
]
],
[
[
245,
40,
1411
],
[
1411,
23,
721
]
],
[
[
245,
24,
127
],
[
127,
23,
721
]
],
[
[
245,
63,
1179
],
[
1179,
... | [
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a ... | Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a minor interaction that can l... |
DB01149 | DB05239 | 851 | 866 | [
"DDInter1274",
"DDInter425"
] | Nefazodone | Cobimetinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
851,
25,
866
]
],
[
[
851,
25,
214
],
[
214,
63,
866
]
],
[
[
851,
63,
888
],
[
888,
24,
866
]
],
[
[
851,
24,
98
],
[
98,
63,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"... | Nefazodone may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cau... |
DB06688 | DB08880 | 1,430 | 1,510 | [
"DDInter1677",
"DDInter1771"
] | Sipuleucel-T | Teriflunomide | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
1430,
24,
1510
]
],
[
[
1430,
24,
36
],
[
36,
25,
1510
]
],
[
[
1430,
24,
637
],
[
637,
64,
1510
]
],
[
[
1430,
63,
147
],
[
147,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Teriflunomide
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi... |
DB00554 | DB00775 | 1,027 | 1,226 | [
"DDInter1478",
"DDInter1818"
] | Piroxicam | Tirofiban | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Moderate | 1 | [
[
[
1027,
24,
1226
]
],
[
[
1027,
24,
714
],
[
714,
63,
1226
]
],
[
[
1027,
63,
1061
],
[
1061,
24,
1226
]
],
[
[
1027,
24,
1512
],
[
1512... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tirofiban"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Tirofiban
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostini... |
DB00656 | DB01233 | 827 | 1,311 | [
"DDInter1851",
"DDInter1197"
] | Trazodone | Metoclopramide | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
827,
24,
1311
]
],
[
[
827,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
827,
64,
1425
],
[
1425,
40,
1311
]
],
[
[
827,
6,
12523
],
[
12523,... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Trazodone may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Trazodone (Co... |
DB00872 | DB08895 | 1,080 | 976 | [
"DDInter438",
"DDInter1825"
] | Conivaptan | Tofacitinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1080,
25,
976
]
],
[
[
1080,
25,
214
],
[
214,
63,
976
]
],
[
[
1080,
24,
86
],
[
86,
24,
976
]
],
[
[
1080,
63,
723
],
[
723,
2... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"... | Conivaptan may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may c... |
DB01028 | DB06704 | 1,332 | 247 | [
"DDInter1179",
"DDInter952"
] | Methoxyflurane | Iobenguane (I-131) | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1332,
24,
247
]
],
[
[
1332,
25,
1527
],
[
1527,
64,
247
]
],
[
[
1332,
25,
497
],
[
497,
25,
247
]
],
[
[
1332,
25,
1527
],
[
1527,
... | [
[
[
"Methoxyflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Methoxyflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
],
[
... | Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Methoxyflurane may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Iobenguane
Methoxyflurane may lea... |
DB00108 | DB08827 | 1,066 | 990 | [
"DDInter1268",
"DDInter1085"
] | Natalizumab | Lomitapide | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1066,
25,
990
]
],
[
[
1066,
25,
973
],
[
973,
24,
990
]
],
[
[
1066,
25,
1362
],
[
1362,
63,
990
]
],
[
[
1066,
64,
268
],
[
268,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u}... | Natalizumab may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Natalizumab may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate intera... |
DB08867 | DB08916 | 807 | 26 | [
"DDInter1897",
"DDInter32"
] | Ulipristal | Afatinib | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
807,
24,
26
]
],
[
[
807,
62,
609
],
[
609,
24,
26
]
],
[
[
807,
24,
710
],
[
710,
63,
26
]
],
[
[
807,
63,
322
],
[
322,
24,
... | [
[
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Ulipristal",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
... | Ulipristal may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and B... |
DB00065 | DB00683 | 581 | 1,382 | [
"DDInter923",
"DDInter1212"
] | Infliximab | Midazolam | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
581,
24,
1382
]
],
[
[
581,
24,
902
],
[
902,
40,
1382
]
],
[
[
581,
25,
1573
],
[
1573,
23,
1382
]
],
[
[
581,
25,
1220
],
[
1220,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Infliximab may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects w... |
DB00543 | DB09272 | 87 | 412 | [
"DDInter82",
"DDInter632"
] | Amoxapine | Eluxadoline | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
87,
24,
412
]
],
[
[
87,
63,
1594
],
[
1594,
24,
412
]
],
[
[
87,
24,
543
],
[
543,
24,
412
]
],
[
[
87,
40,
867
],
[
867,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperam... |
DB00749 | DB01249 | 59 | 258 | [
"DDInter699",
"DDInter958"
] | Etodolac | Iodixanol | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
59,
25,
258
]
],
[
[
59,
25,
497
],
[
497,
1,
258
]
],
[
[
59,
21,
28748
],
[
28748,
60,
258
]
],
[
[
59,
24,
712
],
[
712,
64,
... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Compound) r... | Etodolac may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Etodolac (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Iodixanol (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases wh... |
DB00005 | DB00860 | 1,057 | 891 | [
"DDInter687",
"DDInter1513"
] | Etanercept | Prednisolone | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Major | 2 | [
[
[
1057,
25,
891
]
],
[
[
1057,
25,
175
],
[
175,
40,
891
]
],
[
[
1057,
25,
167
],
[
167,
1,
891
]
],
[
[
1057,
24,
523
],
[
523,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
... | Etanercept may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Etanercept may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisolone (Compound)
Etanercept m... |
DB01232 | DB06203 | 1,327 | 1,002 | [
"DDInter1640",
"DDInter51"
] | Saquinavir | Alogliptin | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1327,
24,
1002
]
],
[
[
1327,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1327,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
1327,
21,
28873
],
[
... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Saquinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Saquinavir (Compound) causes Pancreatitis (Side Effect) and Panc... |
DB00388 | DB00726 | 1,636 | 1,164 | [
"DDInter1453",
"DDInter1876"
] | Phenylephrine | Trimipramine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Major | 2 | [
[
[
1636,
25,
1164
]
],
[
[
1636,
25,
1237
],
[
1237,
40,
1164
]
],
[
[
1636,
24,
939
],
[
939,
40,
1164
]
],
[
[
1636,
64,
21
],
[
21,
... | [
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimipramine"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
... | Phenylephrine may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Trimipramine (Compo... |
DB00911 | DB01073 | 458 | 1,488 | [
"DDInter1811",
"DDInter745"
] | Tinidazole | Fludarabine | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
458,
24,
1488
]
],
[
[
458,
21,
28701
],
[
28701,
60,
1488
]
],
[
[
458,
24,
36
],
[
36,
63,
1488
]
],
[
[
458,
63,
522
],
[
522,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Tinidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is c... | Tinidazole (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Fludarabine (Compound)
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Fludarab... |
DB01126 | DB11837 | 1,260 | 1,297 | [
"DDInter611",
"DDInter1351"
] | Dutasteride | Osilodrostat | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1260,
24,
1297
]
],
[
[
1260,
24,
578
],
[
578,
24,
1297
]
],
[
[
1260,
63,
752
],
[
752,
24,
1297
]
],
[
[
1260,
24,
159
],
[
159,
... | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Ci... |
DB01118 | DB01269 | 33 | 38 | [
"DDInter76",
"DDInter1386"
] | Amiodarone | Panitumumab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006. | Major | 2 | [
[
[
33,
25,
38
]
],
[
[
33,
24,
384
],
[
384,
63,
38
]
],
[
[
33,
63,
92
],
[
92,
24,
38
]
],
[
[
33,
64,
1555
],
[
1555,
24,
... | [
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panitumumab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisi... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Panitumumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Meth... |
DB08911 | DB12010 | 1,556 | 214 | [
"DDInter1842",
"DDInter785"
] | Trametinib | Fostamatinib | Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1556,
24,
214
]
],
[
[
1556,
24,
1155
],
[
1155,
24,
214
]
],
[
[
1556,
63,
1623
],
[
1623,
24,
214
]
],
[
[
1556,
24,
971
],
[
971,
... | [
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
],
[
... | Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and I... |
DB00983 | DB06707 | 480 | 584 | [
"DDInter776",
"DDInter1060"
] | Formoterol | Levonordefrin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
480,
24,
584
]
],
[
[
480,
24,
817
],
[
817,
40,
584
]
],
[
[
480,
24,
1354
],
[
1354,
1,
584
]
],
[
[
480,
24,
1148
],
[
1148,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Levonordefrin (Compound)
... |
DB01015 | DB06589 | 1,247 | 1,250 | [
"DDInter1724",
"DDInter1400"
] | Sulfamethoxazole | Pazopanib | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Minor | 0 | [
[
[
1247,
23,
1250
]
],
[
[
1247,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
1247,
18,
7350
],
[
7350,
57,
1250
]
],
[
[
1247,
21,
28868
],
[
28... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Co... | Sulfamethoxazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Sulfamethoxazole (Compound) downregulates EXT1 (Gene) and EXT1 (Gene) is downregulated by Pazopanib (Compound)
Sulfamethoxazole (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Pazopani... |
DB00559 | DB00603 | 152 | 303 | [
"DDInter223",
"DDInter1137"
] | Bosentan | Medroxyprogesterone acetate | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Major | 2 | [
[
[
152,
25,
303
]
],
[
[
152,
24,
167
],
[
167,
1,
303
]
],
[
[
152,
6,
8374
],
[
8374,
45,
303
]
],
[
[
152,
21,
28956
],
[
28956,
... | [
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Medroxyprogesterone acetate (Compound)
Bosentan (Compound) causes P... |
DB01162 | DB06691 | 195 | 849 | [
"DDInter1767",
"DDInter1155"
] | Terazosin | Mepyramine | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
195,
24,
849
]
],
[
[
195,
63,
770
],
[
770,
24,
849
]
],
[
[
195,
24,
407
],
[
407,
63,
849
]
],
[
[
195,
1,
1433
],
[
1433,
24... | [
[
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
... | Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may c... |
DB00631 | DB00900 | 372 | 45 | [
"DDInter405",
"DDInter544"
] | Clofarabine | Didanosine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
372,
24,
45
]
],
[
[
372,
7,
4071
],
[
4071,
45,
45
]
],
[
[
372,
18,
7212
],
[
7212,
57,
45
]
],
[
[
372,
21,
28709
],
[
28709,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"PNP"
],
[
"PNP",
"{u} (Gene) is bound by {v} (Compound)... | Clofarabine (Compound) upregulates PNP (Gene) and PNP (Gene) is bound by Didanosine (Compound)
Clofarabine (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Didanosine (Compound)
Clofarabine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by D... |
DB00060 | DB00991 | 912 | 97 | [
"DDInter947",
"DDInter1358"
] | Interferon beta-1a | Oxaprozin | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
912,
24,
97
]
],
[
[
912,
24,
362
],
[
362,
1,
97
]
],
[
[
912,
24,
1274
],
[
1274,
24,
97
]
],
[
[
912,
24,
1236
],
[
1236,
40,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Oxaprozin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate inter... |
DB01064 | DB01100 | 1,148 | 1,568 | [
"DDInter987",
"DDInter1470"
] | Isoprenaline | Pimozide | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
1148,
25,
1568
]
],
[
[
1148,
64,
78
],
[
78,
40,
1568
]
],
[
[
1148,
63,
1557
],
[
1557,
25,
1568
]
],
[
[
1148,
18,
2183
],
[
2183,
... | [
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u}... | Isoprenaline may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interaction when ta... |
DB01030 | DB09331 | 869 | 745 | [
"DDInter1835",
"DDInter478"
] | Topotecan | Daratumumab | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
869,
24,
745
]
],
[
[
869,
63,
139
],
[
139,
24,
745
]
],
[
[
869,
24,
4
],
[
4,
24,
745
]
],
[
[
869,
24,
287
],
[
287,
63,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccin... |
DB00063 | DB00500 | 366 | 24 | [
"DDInter659",
"DDInter1831"
] | Eptifibatide | Tolmetin | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Moderate | 1 | [
[
[
366,
24,
24
]
],
[
[
366,
24,
886
],
[
886,
1,
24
]
],
[
[
366,
24,
831
],
[
831,
40,
24
]
],
[
[
366,
64,
1432
],
[
1432,
24,
... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Tolmetin (Compound)
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Tolmetin (Compound... |
DB00424 | DB00909 | 19 | 306 | [
"DDInter896",
"DDInter1971"
] | Hyoscyamine | Zonisamide | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Major | 2 | [
[
[
19,
25,
306
]
],
[
[
19,
21,
28691
],
[
28691,
60,
306
]
],
[
[
19,
24,
407
],
[
407,
63,
306
]
],
[
[
19,
63,
475
],
[
475,
24,... | [
[
[
"Hyoscyamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (... | Hyoscyamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Zonisamide (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Hy... |
DB00857 | DB14730 | 1,387 | 1,412 | [
"DDInter1768",
"DDInter264"
] | Terbinafine | Calaspargase pegol | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1387,
24,
1412
]
],
[
[
1387,
24,
159
],
[
159,
24,
1412
]
],
[
[
1387,
63,
322
],
[
322,
24,
1412
]
],
[
[
1387,
64,
888
],
[
888,
... | [
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Epiru... |
DB00734 | DB00857 | 1,664 | 1,387 | [
"DDInter1605",
"DDInter1768"
] | Risperidone | Terbinafine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Moderate | 1 | [
[
[
1664,
24,
1387
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
1664,
21,
28822
],
[
28822,
60,
1387
]
],
[
[
1664,
62,
752
],
[
75... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terbinafine"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Risperidone (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Terbinafine (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cim... |
DB05679 | DB11703 | 1,683 | 405 | [
"DDInter1907",
"DDInter9"
] | Ustekinumab | Acalabrutinib | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1683,
24,
405
]
],
[
[
1683,
63,
139
],
[
139,
24,
405
]
],
[
[
1683,
24,
951
],
[
951,
24,
405
]
],
[
[
1683,
24,
151
],
[
151,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and ... |
DB00855 | DB00982 | 213 | 1,517 | [
"DDInter72",
"DDInter991"
] | Aminolevulinic acid | Isotretinoin | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Major | 2 | [
[
[
213,
25,
1517
]
],
[
[
213,
64,
640
],
[
640,
25,
1517
]
],
[
[
213,
18,
6168
],
[
6168,
46,
1517
]
],
[
[
213,
7,
7827
],
[
7827,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitre... | Aminolevulinic acid may lead to a major life threatening interaction when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin
Aminolevulinic acid (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is upregulated by Isotretinoin (Compound)
Aminolevulinic... |
DB00348 | DB00976 | 254 | 1,056 | [
"DDInter1300",
"DDInter1758"
] | Nitisinone | Telithromycin | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Moderate | 1 | [
[
[
254,
24,
1056
]
],
[
[
254,
21,
29047
],
[
29047,
60,
1056
]
],
[
[
254,
24,
1220
],
[
1220,
63,
1056
]
],
[
[
254,
24,
663
],
[
663,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatic function abnormal"
],
[
"Hepatic function abnormal... | Nitisinone (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) is caused by Telithromycin (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could ex... |
DB00562 | DB00687 | 1,014 | 870 | [
"DDInter188",
"DDInter747"
] | Benzthiazide | Fludrocortisone | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1014,
24,
870
]
],
[
[
1014,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1014,
63,
251
],
[
251,
40,
870
]
],
[
[
1014,
24,
688
],
[
688,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles F... |
DB00631 | DB08895 | 372 | 976 | [
"DDInter405",
"DDInter1825"
] | Clofarabine | Tofacitinib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
372,
25,
976
]
],
[
[
372,
63,
1461
],
[
1461,
23,
976
]
],
[
[
372,
24,
214
],
[
214,
63,
976
]
],
[
[
372,
24,
998
],
[
998,
2... | [
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fosta... |
DB00524 | DB00983 | 811 | 480 | [
"DDInter1199",
"DDInter776"
] | Metolazone | Formoterol | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
811,
24,
480
]
],
[
[
811,
21,
28963
],
[
28963,
60,
480
]
],
[
[
811,
63,
218
],
[
218,
23,
480
]
],
[
[
811,
24,
870
],
[
870,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused b... | Metolazone (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Formoterol (Compound)
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Beclomethasone dipropionate and Beclomethasone dipropionate may cause a minor interaction that can limit clinical eff... |
DB00586 | DB01222 | 1,512 | 617 | [
"DDInter537",
"DDInter246"
] | Diclofenac | Budesonide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1512,
24,
617
]
],
[
[
1512,
63,
251
],
[
251,
1,
617
]
],
[
[
1512,
24,
175
],
[
175,
1,
617
]
],
[
[
1512,
6,
8374
],
[
8374,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide... |
DB04868 | DB10316 | 478 | 334 | [
"DDInter1293",
"DDInter1248"
] | Nilotinib | Mumps virus strain B level jeryl lynn live antigen | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
478,
25,
334
]
],
[
[
478,
63,
617
],
[
617,
24,
334
]
],
[
[
478,
24,
594
],
[
594,
25,
334
]
],
[
[
478,
64,
1057
],
[
1057,
2... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bude... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Nilotinib may cause a moderate interaction that could exacerbate diseases... |
DB00099 | DB09054 | 440 | 384 | [
"DDInter735",
"DDInter905"
] | Filgrastim | Idelalisib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
440,
24,
384
]
],
[
[
440,
24,
328
],
[
328,
24,
384
]
],
[
[
440,
63,
305
],
[
305,
24,
384
]
],
[
[
440,
24,
1619
],
[
1619,
6... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase ... |
DB05679 | DB06605 | 1,683 | 1,409 | [
"DDInter1907",
"DDInter108"
] | Ustekinumab | Apixaban | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
1683,
24,
1409
]
],
[
[
1683,
63,
58
],
[
58,
24,
1409
]
],
[
[
1683,
24,
1531
],
[
1531,
24,
1409
]
],
[
[
1683,
64,
1057
],
[
1057,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakin... |
DB00289 | DB01191 | 847 | 1,039 | [
"DDInter132",
"DDInter518"
] | Atomoxetine | Dexfenfluramine | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
847,
24,
1039
]
],
[
[
847,
6,
6112
],
[
6112,
45,
1039
]
],
[
[
847,
18,
1954
],
[
1954,
57,
1039
]
],
[
[
847,
40,
211
],
[
211,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Comp... | Atomoxetine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dexfenfluramine (Compound)
Atomoxetine (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Dexfenfluramine (Compound)
Atomoxetine (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a minor interaction that c... |
DB00757 | DB01023 | 1,166 | 409 | [
"DDInter581",
"DDInter716"
] | Dolasetron | Felodipine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Major | 2 | [
[
[
1166,
25,
409
]
],
[
[
1166,
64,
376
],
[
376,
40,
409
]
],
[
[
1166,
64,
1428
],
[
1428,
1,
409
]
],
[
[
1166,
25,
336
],
[
336,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Felodipine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} (... | Dolasetron may lead to a major life threatening interaction when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compound)
Dolasetron may lead to a major... |
DB00502 | DB09054 | 1,300 | 384 | [
"DDInter853",
"DDInter905"
] | Haloperidol | Idelalisib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1300,
24,
384
]
],
[
[
1300,
24,
222
],
[
222,
23,
384
]
],
[
[
1300,
25,
1618
],
[
1618,
24,
384
]
],
[
[
1300,
64,
600
],
[
600,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Haloperidol may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.